Prescription drug abuse remains widespread in the United States, driven by a combination of easier access, changing prescribing practices, online drug markets, and the unique way these medications rewire the brain’s reward system. In 2023, roughly 8.9 million Americans misused opioids, 4.7 million misused tranquilizers or sedatives, and 3.9 million misused prescription stimulants. The forces pushing these numbers aren’t a single cause but a web of overlapping factors, from telehealth loopholes to counterfeit pills laced with fentanyl.
Telehealth Opened New Doors to Controlled Substances
Before the COVID-19 pandemic, federal law required an in-person medical evaluation before a clinician could prescribe controlled substances like stimulants or opioids. That requirement was temporarily waived during the public health emergency, and several telehealth-only companies quickly began offering ADHD treatment and other services that involved prescribing controlled medications. At the peak in April 2020, between 50 and 60 percent of new stimulant prescriptions were initiated through telehealth visits.
By April 2022, those numbers had dropped to 13 percent among children and 28 percent among adults, but the shift had already reshaped how millions of people obtained medications with high abuse potential. The Department of Justice has investigated at least one telehealth firm for possible violations of the Controlled Substances Act related to its stimulant prescribing practices. The core tension remains unresolved: telehealth genuinely improves access for people who need treatment, but a brief video call makes it harder to assess whether a patient is seeking medication for legitimate reasons or for misuse and resale.
How These Drugs Rewire the Brain
Understanding why prescription drugs are so easy to misuse starts with what they do inside the brain. Stimulants, opioids, and sedatives all flood the brain with feel-good chemicals, particularly dopamine, in ways that natural rewards like food or exercise cannot match. Prescription stimulants, for example, block the brain’s normal process of recycling dopamine, leaving more of it available to produce feelings of enhanced mood, motivation, and energy. Amphetamine-based medications go a step further by also increasing the initial burst of dopamine released.
The problem is what happens next. With repeated use, the brain’s dopamine stores become temporarily depleted, producing the depressive, exhausted crash that follows a stimulant wearing off. Over time, the brain also becomes less sensitive to dopamine itself, not just to the medication. This means a person needs more of the drug to feel the same effect (tolerance) and feels worse without it than they did before they ever started taking it. That cycle of diminishing pleasure and deepening withdrawal is the biological engine behind dependence, and it can develop even when someone starts with a legitimate prescription taken at prescribed doses.
Social Media as a Drug Marketplace
Illegal prescription drugs are no longer something you find through word of mouth or a street dealer. They are advertised on platforms used by billions of people every day. Investigations have found that Meta ran dozens of ads on Facebook and Instagram marketing illegal substances, including prescription opioids, with photos of pill bottles and piles of pills directing users to marketplaces on other platforms where purchases could be completed. Meta uses AI tools to moderate this content but has not been able to effectively stop these ads from appearing.
This matters because it lowers the barrier to access dramatically, especially for younger users who may encounter drug ads while scrolling through otherwise ordinary content. The shift from physical transactions to digital ones also makes enforcement far more difficult. Sellers use encrypted apps and frequently change accounts, staying a step ahead of both platform moderators and law enforcement.
Counterfeit Pills Have Made Misuse Deadlier
One of the most dangerous developments fueling the crisis is the explosion of counterfeit prescription pills. These are pills manufactured illegally to look identical to common medications like oxycodone or Xanax but containing fentanyl instead of or in addition to the expected drug. DEA laboratory testing found that six out of ten fentanyl-laced counterfeit pills now contain a potentially lethal dose of fentanyl. A person who believes they are taking a familiar prescription medication may be ingesting something far more powerful, with no way to know the difference by appearance alone.
This has created a grim feedback loop. As legitimate opioid prescriptions have become harder to obtain (partly due to tighter prescribing guidelines), some people turn to the black market, where counterfeit pills are abundant and cheap. The result is that even casual or occasional misuse now carries a much higher risk of fatal overdose than it did a decade ago.
Older Adults Face Unique Risks
Prescription drug misuse is not just a young person’s problem. Nearly one million adults aged 65 and older live with a substance use disorder, and between 4 and 9 percent of older adults use prescription opioids for pain relief. Several factors make this age group particularly vulnerable. Aging bodies metabolize drugs more slowly, so the same dose hits harder and lasts longer. Older brains are also more sensitive to the effects of medications.
Beyond biology, older adults are simply prescribed more medications than any other age group, which increases their exposure to potentially addictive drugs. They are also more likely to unintentionally misuse medications by forgetting doses, taking them too often, or taking the wrong amount. And the emotional dimensions of aging, including retirement, grief, chronic pain, reduced mobility, and social isolation, can push some toward using medications as a coping mechanism rather than strictly as prescribed.
Adolescent Misuse Is Actually Declining
There is one notable bright spot in the data. Among teenagers, prescription drug misuse has been falling for years and continued to decline in 2024. Past-year use of prescription narcotics among 12th graders dropped to 0.6 percent, an all-time low and a dramatic decline from the peak of 9.5 percent in 2004. This suggests that education efforts, prescription drug monitoring programs, and cultural shifts among younger generations have had a real effect, even as misuse persists or grows in other age groups.
Prescribing Guidelines Keep Evolving
The CDC updated its opioid prescribing guidelines in 2022, replacing its 2016 version that had been widely criticized for unintended consequences. The original guidelines included dosage thresholds that many states, insurers, and health systems adopted as rigid cutoffs, leading to patients being abruptly tapered off medications they depended on, dismissed from practices, or denied adequate pain treatment. Cancer and palliative care patients, who were never meant to be covered by the guidelines, were caught up in the restrictions.
The 2022 revision explicitly pushes back against this. It emphasizes that recommendations are voluntary and should be applied flexibly based on individual patient needs, not used as blanket policies. It discourages abrupt tapers and patient abandonment, and it includes new guidance for people already receiving long-term opioid therapy. The goal is to reduce the harms of overprescribing without creating new harms by cutting off people who genuinely need these medications, which can itself drive people toward illicit sources.
The Financial Scale of the Problem
The opioid epidemic alone costs the U.S. healthcare system an estimated $107 billion annually. That figure represents the additional cost of treating individuals with opioid use disorder compared to those without it, roughly $19,000 extra per person per year. These costs fall on private insurers, Medicaid, and hospitals providing uncompensated care. And that number captures only direct healthcare spending. It does not include lost productivity, criminal justice costs, or the incalculable toll on families and communities.
The financial burden creates its own momentum. Strained healthcare systems have fewer resources for prevention and treatment, insurance costs rise for everyone, and communities hardest hit by the crisis face compounding economic disadvantage that makes recovery even harder.